Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Wolverine Stack (BPC-157 + TB-500)
Beginner tier: 500 mcg, daily · 6w on / 2w off · community consensus
Also known as: Wolverine Stack, BPC-157/TB-500 blend, healing stack
Three of four knee pain patients given BPC-157 with thymosin beta-4 reported significant relief, the only published human data on this combination (Lee and Padgett 2021)[7]. The Wolverine Stack is a pre-mixed blend of BPC-157 (5 mg) and TB-500 (5 mg) in a single vial. BPC-157 targets local tissue repair through angiogenesis and receptor upregulation. TB-500 handles the systemic side, driving cell migration and reducing inflammation body-wide. Formal clinical trials on the blend itself don't exist yet. Community reports fill that gap with consistent healing accounts. Athletes, post-surgical patients, and anyone with a stubborn soft tissue injury gravitate to this stack first.
What Is Wolverine Stack (BPC-157 + TB-500)?
Does combining BPC-157 and TB-500 actually produce better healing than either peptide alone? Thousands of community reports say yes. The first controlled animal test, in rats, found no added benefit.
The Wolverine Stack (BPC-157 + TB-500, also called the healing stack) is a pre-mixed 10 mg vial containing 5 mg of each component. BPC-157 is a 15-amino acid fragment of body protection compound, a protein found in human gastric juice. TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) of thymosin beta-4, a 43-amino acid protein involved in cell migration.
The two peptides work through different but complementary mechanisms. BPC-157 upregulates VEGFR2 and FGFR1 receptors at the injury site, promotes angiogenesis, and modulates the nitric oxide system. TB-500 is tied to G-actin binding, angiogenesis and cell migration, mostly from rat and cell studies of full-length thymosin beta-4 [5]. You don't need to inject TB-500 near the injury; it distributes body-wide.
One retrospective chart review followed 16 knee pain patients (Lee and Padgett 2021)[7]. Only 4 received BPC-157 with thymosin beta-4, and 3 of them reported significant relief; 11 of 12 on BPC-157 alone did. A 2026 rat Achilles study (n=32)[6] found the pair no better than either peptide alone; TB-500 alone gave the clearest gains. Beyond that, evidence comes from the individual components: over 180 published BPC-157 papers (35 of 36 studies meeting systematic review criteria were preclinical per Vasireddi et al.)[2]. For TB-500, the closest human data comes from two phase 1 safety trials of its parent protein, full-length thymosin beta-4: Ruff 2010 [8] and Wang 2021 [3].
Community evidence is strong. Tens of thousands of user reports across r/Peptides, ExcelMale, and Longecity consistently describe accelerated soft tissue healing within 2 to 4 weeks. The Wolverine Stack is considered the gold standard healing combination.
FDA's Category 2 page lists both as nominated for compounding, then withdrawn by their nominators. Neither is on the 503A bulks list, so U.S. pharmacies cannot compound them today.
How Wolverine Stack (BPC-157 + TB-500) Works
Two repair systems working different angles from one syringe.
BPC-157 acts at the injury site. It upregulates growth factor receptors VEGFR2 and FGFR1, triggering local angiogenesis. A 2025 review ties that angiogenesis to nitric oxide signaling through the Akt-eNOS axis [1]. In rats, Sikiric and colleagues linked its stomach-lining protection to adrenergic and dopamine systems [4].
TB-500 operates systemically. Its core mechanism is actin sequestration. By binding monomeric G-actin, TB-500 regulates cytoskeletal dynamics that control how quickly cells migrate to injury sites. Much of this comes from full-length thymosin beta-4, the parent protein. Malinda and colleagues found it raised reepithelialization 42% at day 4 and up to 61% at day 7 in rats [5]. Treated rat wounds also showed more collagen deposition and angiogenesis. It inhibits myofibroblast differentiation, which decreases fibrosis and scar tissue formation.
The combination rationale is complementary rather than redundant. BPC-157 handles precision repair at the injection site; TB-500 sends repair signals body-wide regardless of where you inject. That rationale has had one direct test so far. In a 2026 rat Achilles study [6], the pair did no better than either peptide alone. No human pharmacokinetic study exists for the blend.
Wolverine Stack (BPC-157 + TB-500) Benefits
- Wolverine Stack benefits center on tissue repair, pain reduction, and recovery acceleration.
- Accelerated soft tissue healing in two to four weeks. Community consensus across thousands of user reports is remarkably consistent on this timeline for tendons, ligaments, and muscle tears.
- Acute injury pain reduction within one to two weeks. Users frequently report meaningful pain relief before structural healing is complete, attributed to BPC-157 nitric oxide modulation and TB-500 cytokine suppression.
- Post-surgical recovery support. The advanced protocol runs 1,000 mcg a day, split into two injections. Athletes and surgical patients use it for a faster return to function, per community reports.
- Convenience of a single injection. The pre-mixed 1:1 blend eliminates the need to reconstitute and inject two separate vials.
- Chronic tendinopathy response after four to six weeks. Repetitive strain injuries and long-standing tendon issues represent a slower but commonly reported response window.
- Complementary local plus systemic coverage. BPC-157 targets the injury site through angiogenesis and VEGFR2 upregulation while TB-500 drives repair signals systemically through actin sequestration, cell migration, and angiogenesis. Those findings come from rats given full-length thymosin beta-4 [5]. Users consistently perceive the combination as superior to either peptide alone, though the one controlled rat study [6] found no added benefit.
Wolverine Stack (BPC-157 + TB-500): Science vs Community Consensus
No published RCT or clinical trial specifically tests the BPC-157 + TB-500 combination as a pre-mixed formulation.
Read the evidence (key study, limitations)
One retrospective chart review (Lee & Padgett 2021, n=16 knee pain patients)[7] gave 4 patients BPC-157 + thymosin beta-4; 3 of 4 reported significant pain relief: the only published human data on the combination. Individual component science is largely preclinical: over 180 papers on BPC-157 (35 of 36 meeting systematic review inclusion were preclinical; Vasireddi et al.)[2]. TB-500 itself has no published human study; two phase 1 trials, Ruff 2010 [8] and Wang 2021 [3], tested full-length thymosin beta-4. The combined Wolverine Stack has no dedicated human trial. Mechanistic rationale for pairing them: BPC-157 acts locally (VEGFR2/FGFR1 upregulation, angiogenesis, nitric oxide modulation) while TB-500 acts systemically (actin sequestration, cell migration, VEGF upregulation). The first controlled animal test of the pair (rat Achilles tendon, n=32)[6] found the combination conferred no additional benefit over either agent alone. TB-500 alone improved load to failure and histology scores; BPC-157 alone did not reach significance.
Lee & Padgett 2021 (PMID 34324435; retrospective, n=16, knee pain): 4 received BPC-157 with thymosin beta-4 and 3 of 4 reported significant relief; 11 of 12 on BPC-157 alone did. Only published human data combining the two.
No dedicated RCT. Only one retrospective human report includes the combination (4 patients, PMID 34324435). All other evidence is animal-based. No human dose-finding or PK study for the blend. Ratio locked at 1:1 in pre-mixed vials prevents independent component titration. Combination angiogenic safety (pro-tumor vascularization risk) has not been evaluated in humans.
Strong community consensus.
Read the reports (what users report 7, common issues 8)
The Wolverine Stack is one of the most established peptide combinations. Tens of thousands of users report consistent outcomes. Protocol agreement is high across r/Peptides, ExcelMale, and practitioner guides. Considered the gold standard healing stack.
- Accelerated soft tissue healing (tendons, ligaments, muscle tears): most users report meaningful improvement in 2–4 weeks
- Acute injury pain reduction within 1–2 weeks
- Improved flexibility and range of motion around injured areas
- Post-surgical recovery acceleration
- Convenience: one injection covers both peptides
- Combination perceived as superior to either component alone
- Chronic tendinopathy and repetitive strain injuries often respond after 4–6 weeks
- Nausea: most common complaint, attributed to BPC-157 gastric motility effects; worse at higher doses
- Headaches during loading phase: attributed to vasodilation
- "Peptide flu" in weeks 1–2: malaise, chills, transient fatigue; usually resolves
- Injection site reactions: redness, lumps; often due to BAC water pH or benzyl alcohol, not the peptide
- Heart palpitations: transient, most common in first few days
- Anxiety or panic attacks in a subset of users (BPC-157 serotonin/dopamine modulation)
- Pre-mixed ratio cannot be adjusted: users who need higher TB-500 dosing must supplement with separate TB-500 vials
- Zero effect in some users: frequently attributed to counterfeit or degraded product
Science supports both individual components via preclinical evidence and one retrospective human combination report. Community protocol is mechanistically coherent with published science. Divergence exists on: (1) optimal dosing: community uses fixed 1:1 ratio from pre-mixed vial while science would support independent component titration; (2) loading structure: community adds TB-500-style loading to a daily BPC-157 protocol; (3) confidence ceiling: community treats this as well-established while evidence is still primarily animal-based.
Wolverine Stack (BPC-157 + TB-500) Dosage Guide
The dosing math on a 10 mg pre-mixed vial (5 mg BPC-157 + 5 mg TB-500) reconstituted with 2 mL bacteriostatic water: 5,000 mcg/mL total (2,500 mcg/mL each component). On a U-100 insulin syringe: 5 units = 250 mcg total, 10 units = 500 mcg total, 20 units = 1,000 mcg total.
Start at the beginner dose (500 mcg/day, which is 10 units). Most people tolerate it without issues. If nausea hits, drop to 5 units for a few days and work back up.
Inject as close to the injury as you can safely reach subcutaneously. For deeper structures like Achilles or rotator cuff, inject into subcutaneous tissue directly above. BPC-157 benefits from proximity; TB-500 goes everywhere regardless.
One thing beginners miss: product quality matters more with blends. Require LC-MS/MS confirmation that both BPC-157 (MW 1419.5 Da) and TB-500 (MW 889.0 Da) are present at correct masses. HPLC alone can't distinguish closely related impurities in peptide blends.
Cycling Protocol
Loading phase: full dose daily for 4-6 weeks. Then maintenance: half dose every other day. The TB-500 component benefits from a loading protocol.
Both components individually are cycled 6 weeks on / 2 weeks off by community consensus. The rationale is: (1) TB-500 loading structure (higher dose for 4–6 weeks, then maintenance or rest) follows a standard loading protocol for peptides with systemic accumulation; (2) BPC-157 theoretical receptor desensitization: no formal data but consistent with peptide receptor downregulation principles; (3) safety monitoring: the 2-week off period allows assessment of any adverse effects before re-loading; (4) no published human safety data exists for TB-500 at any duration, and none for BPC-157 beyond a few weeks. The combined cycle follows whichever component has the more conservative cycling requirement.
- Diminishing healing response despite continued dosing (suggests desensitization or resolved injury)
- Persistent anxiety, mood changes, or palpitations beyond week 3 (suggests CNS sensitization)
- New or worsening nausea after week 2 (expected in week 1 only)
- Injection site reactions that are not resolving with site rotation
Or use the universal Peptide Calculator for any peptide.
Wolverine Stack (BPC-157 + TB-500) Protocols by Goal
Expected: Pain reduction and improved function within 2–4 weeks; significant healing by week 6. Community reports ~70–80% of users notice meaningful improvement within one loading cycle.
Monitor: Monitor for anxiety, palpitations (BPC-157 dopamine modulation). Watch for signs of healing overshooting: increased local swelling or warmth after week 4 can indicate excessive angiogenesis response.
How to Use Wolverine Stack (BPC-157 + TB-500)
- 1Reconstitute the 10 mg vial with 2 mL bacteriostatic water
Aim the stream along the glass wall. Do not shake. Swirl gently until dissolved (2 to 3 minutes). This gives you 5,000 mcg/mL total.
- 2Step 2
Draw your dose with a U-100 insulin syringe (29 to 31 gauge). Beginner: 10 units = 500 mcg total (250 mcg each component). Moderate: 20 units = 1,000 mcg total, once a day. Aggressive: the same 20 units once a day, because 1,000 mcg a day is the community ceiling; the post-op protocol splits it into two 10-unit draws. No published source sets a dose for the blend; these are community figures.
- 3Clean the injection site with an alcohol swab
Abdomen (two inches from navel), thigh, or subcutaneous tissue directly above the injury. BPC-157 works best locally.
- 4Pinch a fold of skin
Insert the needle at a 45-degree angle. Push the plunger slowly. Release the skin, withdraw the needle, apply light pressure.
- 5Rotate injection sites daily
If injecting near an injury, alternate between two spots on opposite sides of the affected area.
- 6Standard timing is morning before activity
For the twice-daily advanced protocol, space injections 8 to 12 hours apart.
- 7Step 7
Store the reconstituted vial in the refrigerator at 2 to 8 degrees C. Use within 3 to 4 weeks. Never freeze reconstituted solution.
Alternative Routes
BPC-157 alone is acid-stable and used orally for gut healing at 500 mcg. However, the TB-500 component has no established oral bioavailability: it would be degraded in the GI tract. For oral gut healing, standalone BPC-157 is required; the pre-mixed vial should not be used orally.
If the goal is gut healing specifically, use standalone BPC-157 oral. The Wolverine Stack pre-mixed vial is subcutaneous only.
Same dose, different absorption kinetics. BPC-157 benefits from proximity to injury (SQ preferred). TB-500 is fully systemic regardless of route.
IM injection acceptable if preferred. Glute or deltoid common sites. SQ is preferred for the blend because BPC-157 local healing effect is preserved.
Wolverine Stack (BPC-157 + TB-500) Stacking Protocols
Works With
Copper peptide adds collagen synthesis, ECM remodeling, and skin/connective tissue repair on top of the angiogenic healing provided by BPC-157 + TB-500. The canonical advanced healing trio is BPC-157 (local angiogenesis), TB-500 (systemic migration), and GHK-Cu (collagen quality).
SQ or topical, daily, alongside Wolverine Stack injection
Potent anti-inflammatory tripeptide (α-MSH fragment). Reduces systemic inflammation that can impede healing. Stacked to address the inflammatory component while BPC-157 and TB-500 handle structural repair.
SQ daily or oral
GHRH analogue increases IGF-1 signaling, supporting satellite cell repair and muscle protein synthesis alongside the structural healing from the Wolverine Stack. Commonly combined as the "complete recovery stack."
Evening SQ injection, separate from Wolverine Stack
Selective GH secretagogue from the GHRP-1 compound series (PMID 9849822), paired with CJC-1295 for pulsatile GH release and IGF-1 support. Adds anabolic recovery signaling to complement the Wolverine Stack healing mechanisms.
Evening SQ injection paired with CJC-1295
Avoid
Directly opposes the angiogenic mechanism of both BPC-157 (VEGFR2 upregulation) and TB-500 (angiogenesis in rat studies of thymosin beta-4). Combining nullifies both peptide effects and may produce unpredictable vascular signaling.
Do not combineIn rats, BPC-157 interacts with dopamine and adrenergic systems (PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385). Multiple community reports of worsened anxiety and panic attacks when combining BPC-157 with antidepressants. No human interaction study exists but mechanism is plausible. Discuss with prescriber.
Both BPC-157 and TB-500 promote angiogenesis, which may increase bleeding risk at healing sites. The combination amplifies this concern vs. either peptide alone.
TB-500 modulates immune cell migration; BPC-157 modulates leukocyte recruitment. Combined effect on immunosuppressive therapy is unknown. Theoretical risk of undermining therapeutic immunosuppression.
Estimated Cost
Pricing updated 2026-04-09
Wolverine Stack (BPC-157 + TB-500) Side Effects
The most serious safety concern with the Wolverine Stack is its pro-angiogenic load. Both BPC-157 and TB-500 promote new blood vessel formation through different receptor pathways. In someone with an undiagnosed or subclinical tumor, that combined vascularization signal could theoretically support cancer growth. No human oncogenic data exists for either peptide, but the mechanism is real. Cancer screening before starting any cycle is not optional.
Anxiety and panic attacks affect a subset of users. In rats, BPC-157 interacts with dopamine and adrenergic systems (Sikiric et al.)[4] and shifts brain serotonin synthesis [9]. Multiple community reports describe worsened anxiety when combining BPC-157 with SSRIs or SNRIs. Users on antidepressants should discuss this with their prescriber before starting. If anxiety occurs, reducing to 250 mcg total per day or discontinuing the BPC-157 component specifically is the standard community approach. The TB-500 component alone does not trigger this effect.
Heart palpitations are transient and most common in the first few days. They typically resolve without intervention.
Nausea is the most frequently reported side effect overall. The BPC-157 component increases gastric motility, and higher doses make it worse. Injecting before bed rather than morning helps for most users. If nausea persists past week 2, suspect product quality; mannitol filler and residual acetonitrile from HPLC purification are common culprits in research-grade vials.
"Peptide flu" hits some users in weeks one and two: malaise, chills, transient fatigue. This usually resolves by week three. Headaches during loading are attributed to vasodilation from the combined angiogenic response.
Injection site reactions (redness, lumps, nodules) are often caused by benzyl alcohol in bacteriostatic water rather than the peptides themselves. Switching to preservative-free sterile water reduces reactions but shortens reconstituted shelf life. Any lump larger than 1 cm persisting beyond week two warrants medical evaluation.
Human safety data is extremely limited. Total published human evidence for the combination is 4 patients in one retrospective report (Lee and Padgett 2021)[7]. TB-500 itself has no published human safety data; FDA found none by any route. Two phase 1 trials, Ruff 2010 [8] and Wang 2021 [3], gave intravenous full-length thymosin beta-4 instead. BPC-157 has no completed human safety trial. Third-party testing has found inconsistent purity and labeling among research-grade peptide products. Pre-mixed blends face additional risk: if either component is compromised, the entire vial is affected.
Contraindications: active cancer or cancer history, pregnancy or breastfeeding, active systemic infections, and known hypersensitivity to BPC-157, thymosin beta-4, or formulation components.
When to stop: fever above 100.4 degrees F, rash, hives, worsening palpitations, severe anxiety, any sign of infection spreading. Do not push through these symptoms.
Common Issues & Solutions
Nausea within 30–60 minutes of injection: usually BPC-157-mediated gastric motility effect. Reduce dose by 50%; try injecting before bed rather than morning. If persists, rule out impure product (mannitol filler, residual acetonitrile from HPLC).
No effect after 3 weeks at 500 mcg/day: suspect product quality first: research-grade products have a high failure rate (68% mislabeled per 2025 purity audit). Verify COA (LC-MS preferred over HPLC alone). Second possibility: injury type not responsive: nerve injuries and cartilage respond slower or less reliably than tendon/ligament.
Pre-mixed vial dosing math: 10mg vial + 2mL BAC water = 5,000 mcg/mL total (2,500 mcg/mL each component). 5 units on U-100 syringe = 250 mcg total. 10 units = 500 mcg total. 20 units = 1,000 mcg total.
Injection site lumps or nodules: usually caused by benzyl alcohol in bacteriostatic water or improper injection depth. Rotate sites more aggressively. Switch to preservative-free sterile water if persistent (shorter shelf life but fewer reactions). Aspirate any lump >1cm that appears after week 2: deeper investigation warranted.
Ask AI about this page
Ask AI for a second opinion on Wolverine Stack (BPC-157 + TB-500) dosing and side effects
Contraindications
- Active cancer or personal history of cancer: both components promote angiogenesis, which may support tumor vascularization
- Pregnancy or breastfeeding: no safety data available
- Active systemic infections: enhanced cell migration could theoretically spread pathogens
- Known hypersensitivity to BPC-157, thymosin beta-4, or any formulation component
Drug Interactions
- Anticoagulants (warfarin, heparin, DOACs): both components promote angiogenesis and may increase bleeding risk
- Anti-VEGF therapies (bevacizumab): directly opposes the angiogenic mechanism of both peptides
- Immunosuppressants: TB-500 modulates immune cell migration; effects on immunosuppressive therapy are unknown
- NSAIDs: may partially counteract the inflammatory modulation; use is common but monitor healing progress
Product Quality
Neither BPC-157 nor TB-500 is on the 503A bulks list, so licensed pharmacies cannot compound them today. All available product is an unregulated research chemical. A 2025 purity audit found 68% of peptide products mislabeled or containing impurities (Finnrick Analytics, 450 samples, 64 companies). Pre-mixed blends face additional quality risk: if either component is contaminated or misdosed, the entire vial is compromised. No FDA-regulated compounded product exists, and FDA has proposed no rule adding either to the 503A bulks list.
- Require both HPLC and LC-MS/MS certificates of analysis: HPLC alone cannot distinguish closely related impurities in peptide blends
- Look for mass spec confirmation that both BPC-157 (MW 1419.5 Da) and TB-500 (MW 889.0 Da) are present at the correct masses
- Third-party testing preferred over an in-house COA: send a sample to Janoshik or Quality Peptides Testing if in doubt
- Check for mannitol filler ratio: some products contain excessive filler, effectively under-dosing active peptide
- Pre-mixed vials degrade faster than single-component vials: check reconstitution date and use within 3–4 weeks once reconstituted
- A batch-specific COA ties a test result to one lot number; a generic COA without a lot number says little about the vial in hand
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Cancer screening (clinical exam, PSA if male) | Before starting any cycle | No active malignancy confirmed before proceeding |
| Complete blood count (CBC) + comprehensive metabolic panel (CMP) | Baseline before starting; repeat at week 8 for cycles >6 weeks | Not listed |
| Injection site inspection | Before each injection | Not listed |
Both BPC-157 and TB-500 promote angiogenesis. Combined pro-angiogenic load could theoretically support vascularization of subclinical tumors. Strong contraindication in anyone with active cancer or history.
No specific BPC-157/TB-500 combination toxicity markers are established. Baseline provides reference for any unexpected changes in hepatic, renal, or hematologic parameters during use.
Nodules, blistering, or increasing redness at prior injection sites may indicate reaction to formulation excipients or early infection. TB-500-related site reactions are more common during loading phase.
Wolverine Stack (BPC-157 + TB-500) Before and After
Loading phase begins. Mild improvements in pain and inflammation may be noticed. BPC-157 begins local repair signaling while TB-500 reduces systemic inflammation.
Noticeable improvement in pain levels, flexibility, and range of motion. Angiogenesis accelerates tissue repair at the injury site.
Significant healing progress. Many users report substantially reduced pain and improved function. End of loading phase.
Transition to maintenance dosing. Continued healing support. Reload at full dose if a new injury occurs.
What to Expect
Days 1 through 7 (Onset and Systemic Distribution): BPC-157 plasma half-life runs under 30 minutes, but functional receptor upregulation begins within hours. TB-500 distributes systemically from the first injection. Many users pick up a slight reduction in acute pain by day three to five. Some report warmth or tingling at the injury site. Others feel nothing the first week. Nausea, mild headache, and the so-called "peptide flu" (malaise, chills) are most common during this window.
Weeks 2 through 3 (Early Structural Response): Angiogenesis kicks in. Thymosin beta-4 (the parent protein of TB-500) increased angiogenesis in healing rat wounds [5]. Most users land on their first real improvement here: less pain, better flexibility, early range-of-motion gains. Acute injuries respond faster than chronic ones. Side effects from week one typically fade.
Weeks 4 through 6 (Peak Loading Phase): Peak collagen deposition and tissue remodeling hit their stride in preclinical models. Rat wound data for full-length thymosin beta-4 show up to 61% more reepithelialization at day 7 versus controls (Malinda et al.)[5]. The majority of users report real functional improvement. Athletes often return to modified training. Chronic conditions show progress but don't always fully resolve in one cycle.
Weeks 7 through 8 (Maintenance or Off-Ramp): Users drop to half-dose or every-other-day frequency. Many stop entirely and assess. Some find the results stick; injury healed, no regression. Complex injuries (ACL, rotator cuff) may need a second loading cycle after two to four weeks off. Community protocols space out TB-500 doses on the belief that its effect lasts 7 to 10 days; no human half-life study supports that figure.
Detailed Timeline: Science vs Community
BPC-157 plasma half-life <30 minutes; functional activity via receptor upregulation begins within hours of first dose. TB-500 distributes systemically, reaching injury sites regardless of injection location.
Many users notice slight reduction in acute pain and inflammation by day 3–5. Some report "warmth" or tingling at the injury site: attributed to initial angiogenesis signaling. Others feel nothing for the first week.
Angiogenesis begins generating new capillary networks at injury sites. In rats, full-length thymosin beta-4 increased wound angiogenesis by day 7 (PMID 10469335). Cell migration to damaged areas accelerates.
Most users report their first significant improvement here: pain reduction, improved flexibility, and early range-of-motion restoration. Acute injuries show faster response than chronic.
Peak collagen deposition and tissue remodeling phase in preclinical models. Full-length thymosin beta-4 raised reepithelialization up to 61% at day 7 in rat wounds (Malinda et al. PMID 10469335); TB-500 itself was not tested.
Majority of users report significant functional improvement. Athletes often return to modified training. Pain substantially reduced or eliminated for acute injuries. Chronic conditions showing improvement but not always complete resolution.
Continued receptor desensitization possible with daily dosing. TB-500 maintenance dosing rests on community reports of a 7–10 day effect; no human half-life study supports it. No published tolerance data for the combination.
Users transition to half-dose or every-other-day maintenance. Many stop entirely and assess. Some report results "locked in": injury healed, no regression after stopping. Complex injuries (ACL, rotator cuff) may need a second cycle.
Pharmacokinetics
Source: Estimated from component half-lives: BPC-157 plasma t1/2 ~30 min (functional ~4h), TB-500 plasma t1/2 ~5h. Blend half-life reflects the shorter-acting component for dosing purposes.
Pharmacokinetics: Active Dose Over Time
t½ = ~4-6 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Wolverine Stack (BPC-157 + TB-500) Legal?
BPC-157 and TB-500 were both on the FDA Category 2 bulk drug substance list until their nominators withdrew them; FDA's Category 2 page (current as of April 22, 2026) lists both as withdrawn. Licensed U.S. compounding pharmacies cannot produce either component or the pre-mixed blend today. PCAC discussed both on July 23, 2026, and no FDA rule has added either to the 503A bulks list.
All currently available Wolverine Stack product is an unregulated research chemical. It is sold labeled "for research purposes only" and is not approved for human use by the FDA or any regulatory agency.
WADA's 2026 Prohibited List bans both components in and out of competition. BPC-157 is named under S0 (non-approved substances); TB-500 is named under S2.3 (thymosin-β4 and its derivatives). Athletes subject to anti-doping testing should not use this product.
This content is for informational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any peptide product.
Who Should Consider Wolverine Stack (BPC-157 + TB-500)
- Athletes recovering from soft tissue injuries (tendons, ligaments, muscle tears)
- Post-surgical patients seeking accelerated wound healing
- Individuals with chronic tendinopathy or repetitive strain injuries
- Those seeking a convenient single-injection healing protocol combining BPC-157 and TB-500
Related Peptides
What Changed for Wolverine Stack (BPC-157 + TB-500)
- Regulatory
Corrected Oct 15, 2026: the Wolverine Stack now carries a sourced US status: none listed in Drugs@FDA, both components withdrawn from category 2, per FDA.
Before: No sourced US status record After: Unapproved in the US; no application in Drugs@FDA; BPC-157 and TB-500 sit on FDA's nominated-but-withdrawn table, off the 503A bulks list
What this does not mean: Nothing changed at FDA. Neither BPC-157 nor TB-500 is on the 503A bulks list, and no proposed or final rule adds either (Federal Register search, Oct 15, 2026).
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy
- Evidence
Corrected Oct 15, 2026: the Wolverine Stack's side effects no longer credit TB-500 with a phase 1 safety study; none has given it to people, per FDA.
Before: TB-500 has one Phase I safety study (PMID 34346165) After: TB-500 itself has no published human safety data; two phase 1 trials gave intravenous full-length thymosin beta-4 (PMID 20536472, PMID 34346165)
What this does not mean: The two phase 1 trials (PMID 20536472, PMID 34346165) tested intravenous full-length thymosin beta-4, the parent protein, not the TB-500 fragment in the blend. The BPC-157 line is unchanged.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy
- Evidence
Corrected Oct 15, 2026: the Wolverine Stack serotonin line now cites a 2004 rat brain study, not a dopamine paper, per PubMed (PMID 15531385).
Before: BPC-157 modulates serotonin and dopamine pathways (cited to PMID 9073154, an adrenergic and dopamine paper) After: In rats, BPC-157 interacts with dopamine and adrenergic systems (PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385)
What this does not mean: The warning is unchanged. Anxiety and mood effects remain community reports, and the rat data only make them plausible. PMID 9073154 still backs the dopamine and adrenergic link.
Source: Life Sci 2004, Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama, Sikiric and Diksic) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
Corrected Oct 15, 2026: the Wolverine Stack now reads Limited Research; the only controlled test of the pair was in rats, per Jt Dis Relat Surg (PMID 42542926).
Before: well-researched After: limited-research
What this does not mean: Dose tiers are unchanged. Each component has its own studies; no human trial has tested the pre-mixed blend, and 4 patients in one chart review got BPC-157 with thymosin beta-4.
Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Regulatory
Corrected Oct 15, 2026: the Wolverine Stack page no longer calls BPC-157 and TB-500 "FDA-prohibited"; both left category 2, per FDA.
What this does not mean: Neither peptide is on the 503A bulks list, so pharmacies still cannot compound them. No proposed or final rule exists (Federal Register search, Oct 15, 2026).
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 15, 2026: the Wolverine Stack's top tier is now 1,000 mcg once a day, not 1,500 mcg twice a day; no human dose exists, per FDA's TB-500 briefing.
Before: Aggressive 1,500 mcg total twice daily (3,000 mcg a day); post-op protocol 1,000 mcg twice daily; FAQ 500 mcg BPC-157 plus 1,000 mcg TB-500; none sourced After: Aggressive 1,000 mcg total once daily, equal to moderate (the community ceiling); the post-op protocol, guide, benefits and FAQ cap at 1,000 mcg a day, labelled community reports
What this does not mean: The beginner and moderate tiers are unchanged; the top tier now equals moderate. 1,000 mcg a day is a community figure, not a studied dose. FDA found no human data for TB-500.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for TB-500-related bulk drug substances, July 23-24, 2026 (memo dated May 15, 2026): 'FDA is particularly concerned about the absence of human data on drug products containing these substances administered via any ROA' (p. 32) (opens in a new tab) · Saved copy
- Evidence
Corrected Oct 7, 2026: 4 of 16 knee pain patients in Lee and Padgett 2021 got BPC-157 with thymosin beta-4, not all 16, per PubMed (PMID 34324435).
Before: Human combination evidence: one retrospective report of 16 patients (Lee and Padgett 2021) After: Human combination evidence: 4 patients in one retrospective report (Lee and Padgett 2021, PMID 34324435)
What this does not mean: The other 12 patients received BPC-157 alone. Three of the four combination patients reported significant relief; the study was a retrospective chart review with no control group.
Source: Altern Ther Health Med 2021, Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee and Padgett) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Evidence
In rats, BPC-157 plus TB-500 gave no added Achilles tendon benefit over either peptide alone, per Jt Dis Relat Surg, Jul 23, 2026.
What this does not mean: One small rat study: 8 rats per group, 4 weeks of intraperitoneal injections. It did not test people or the pre-mixed vial, and it does not show the stack slows healing.
Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 8, 202614 Citations
References
- [1]Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Curr Rev Musculoskelet Med 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (HSS J 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]A first-in-human, randomized, double-blind, phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers (Wang et al., J Cell Mol Med 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress (Sikiric et al., Dig Dis Sci 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Thymosin beta4 accelerates wound healing (Malinda et al., J Invest Dermatol 1999) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study (Biçer et al., Jt Dis Relat Surg 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (Lee and Padgett 2021) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (Ruff et al., Ann N Y Acad Sci 2010) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama et al., Life Sci 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al., J Appl Physiol 2011) (opens in a new tab)PubMed 21030672PubMed
- Thymosin beta4 and cardiac repair (Shrivastava et al., Ann N Y Acad Sci 2010; full-length thymosin beta-4, not TB-500) (opens in a new tab)PubMed 20536454PubMed
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (Rahman et al., J Am Acad Orthop Surg Glob Res Rev 2026) (opens in a new tab)PubMed 41490200PubMed
- FDA briefing document: TB-500 for the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 15, 2026): no clinical studies or human exposure data by any route (opens in a new tab)Review
- FDA briefing document: BPC-157 for the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): five small clinical studies, none by subcutaneous injection (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Wolverine Stack (BPC-157 + TB-500)?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 300-600. Community mentions on Reddit: ~300-600 threads (r/Peptides: top healing stack). Open r/Peptides (opens in a new tab).
2 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.